COVID-19: Vaccines and Therapeutics
This page includes digital content and resources related to COVID-19 and communities of color. This page will be continuously updated with content as it becomes available.
The Department of Health and Human Services today will amend the Public Readiness and Emergency Preparedness Act to permit doctors and nurses who have recently retired or become inactive to administer COVID-19 vaccines and anyone currently licensed to vaccinate in their state to administer shots…
President Biden announced the federal government will purchase an additional 200 million doses of the two COVID-19 vaccines authorized by the Food and Drug Administration for emergency use.
Drug maker Eli Lilly and Company said its neutralizing antibodies cocktail of bamlanivimab and etesevimab combine to significantly reduce hospitalizations and deaths attributed to COVID-19.
Regeneron Pharmaceuticals Inc. announced interim data indicating that its REGEN-COV antibody cocktail could be used as a passive vaccine to prevent COVID-19.
Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed.
This year, I look forward to continuing AHA’s Leadership Rounds, short conversations on trending topics with health care leaders from around the country.
The Centers for Disease Control and Prevention reported 10 cases of anaphylaxis, a life-threatening allergic reaction, among the more than 4 million people who received a first dose of the Moderna COVID-19 vaccine between Dec. 21, 2020, and Jan. 10, 2021.
Full-dose blood thinner treatments can reduce the need for vital organ support such as ventilation in moderately ill patients hospitalized for COVID-19, according to interim results from a clinical trial announced by the National Institutes of Health.
“We have much to do, much to repair, much to restore, much to heal, much to build … and much to gain.”